Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study

Authors

Institutions

Publication Details

Journal
BMC Medicine
Published
2026-01-16
DOI
https://doi.org/10.1186/s12916-025-04597-8
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study

Shuqing Wei, Changlu Hu, Guanghai Dai, Ruihong Dai et al.
BMC Medicine
Monoclonal and Polyclonal Antibodies Research
article

Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study

Shuqing Wei, Changlu Hu, Guanghai Dai, Ruihong Dai, Qian Wu, Dong Hua, J. Ying, M. Zhang, Qi Xu, Yulong Zhang, Yuping Sun, Jihui Hao, Xiaoyu Li, Zuoxing Niu, Xin Wang, Li Zheng, Hui Zhou, Feng Bi, Zengqing Guo, Xiaobing Chen
article en

Abstract

No abstract available for this paper.
BMC MedicineVol. 24(1)
Anhui Medical University (CN), National Medical Products Administration (CN), Sichuan University (CN), Tianjin Medical University Cancer Institute and Hospital (CN), Chinese PLA General Hospital (CN), Shanghai Innovative Research Center of Traditional Chinese Medicine (CN), Zhejiang Cancer Hospital (CN), Shandong Tumor Hospital (CN), Shanxi Provincial Cancer Hospital (CN), Sichuan Cancer Hospital (CN), Wuxi No.2 People's Hospital (CN), Anhui Provincial Hospital (CN), Henan Cancer Hospital (CN), Fujian Provincial Cancer Hospital (CN), Second Affiliated Hospital of Anhui Medical University (CN), Shanghai Clinical Research Center (CN), Wuxi People's Hospital (CN), Fourth Affiliated Hospital of Anhui Medical University (CN), Shandong First Medical University (CN), Innovative Biologics (United States) (US)
Good health and well-being
Openalex Percentile: Top 88%
Monoclonal and Polyclonal Antibodies Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study — Shuqing Wei, Changlu Hu, et al. · BMC Medicine (2026) | TGRS Research Map | TGRS